118 related articles for article (PubMed ID: 34034308)
41. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
[TBL] [Abstract][Full Text] [Related]
42. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
Blakkisrud J; Løndalen A; Martinsen AC; Dahle J; Holtedahl JE; Bach-Gansmo T; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):48-54. PubMed ID: 27493270
[TBL] [Abstract][Full Text] [Related]
43. Kidney Doses in
Mix M; Renaud T; Kind F; Nemer U; Yousetzadeh-Nowsha E; Moalosi TCG; Ormrane AM; Meyer PT; Ruf J
J Nucl Med; 2022 Feb; 63(2):253-258. PubMed ID: 34088773
[TBL] [Abstract][Full Text] [Related]
44. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
Breitz H; Wendt R; Stabin M; Bouchet L; Wessels B
Cancer Biother Radiopharm; 2003 Apr; 18(2):225-30. PubMed ID: 12804048
[TBL] [Abstract][Full Text] [Related]
45. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
Örbom A; Eriksson SE; Elgström E; Ohlsson T; Nilsson R; Tennvall J; Strand SE
J Nucl Med; 2013 Aug; 54(8):1404-10. PubMed ID: 23804328
[TBL] [Abstract][Full Text] [Related]
46. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
47. Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.
Meckel M; Nauth A; Timpe J; Zhernosekov K; Puranik AD; Baum RP; Rösch F
Cancer Biother Radiopharm; 2015 Mar; 30(2):94-9. PubMed ID: 25714451
[TBL] [Abstract][Full Text] [Related]
48. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
49. Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice.
Vilchis-Juárez A; Ferro-Flores G; Santos-Cuevas C; Morales-Avila E; Ocampo-García B; Díaz-Nieto L; Luna-Gutiérrez M; Jiménez-Mancilla N; Pedraza-López M; Gómez-Oliván L
J Biomed Nanotechnol; 2014 Mar; 10(3):393-404. PubMed ID: 24730235
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
Vallabhajosula S; Kuji I; Hamacher KA; Konishi S; Kostakoglu L; Kothari PA; Milowski MI; Nanus DM; Bander NH; Goldsmith SJ
J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
[TBL] [Abstract][Full Text] [Related]
51. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
[TBL] [Abstract][Full Text] [Related]
52. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
Schoffelen R; Woliner-van der Weg W; Visser EP; Goldenberg DM; Sharkey RM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1593-602. PubMed ID: 24643780
[TBL] [Abstract][Full Text] [Related]
53. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
54. Dosimetry Estimate and Initial Clinical Experience with
Rathke H; Flechsig P; Mier W; Bronzel M; Mavriopoulou E; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C
J Nucl Med; 2019 Jun; 60(6):806-811. PubMed ID: 30389816
[TBL] [Abstract][Full Text] [Related]
55. Comparative studies on the potential use of
Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
[No Abstract] [Full Text] [Related]
56.
Vallejo-Armenta P; Santos-Cuevas C; Soto-Andonaegui J; Villanueva-Pérez RM; González-Díaz JI; García-Pérez FO; Arrellano-Zarate A; Luna-Gutiérrez M; Azorín-Vega E; Ocampo-García B; Ferro-Flores G
Contrast Media Mol Imaging; 2020; 2020():2525037. PubMed ID: 32410920
[TBL] [Abstract][Full Text] [Related]
57. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
58. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
59. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
J Nucl Med; 2016 Jun; 57(6):936-42. PubMed ID: 26848176
[TBL] [Abstract][Full Text] [Related]
60. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]